Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation

• প্রধান লেখক: Natalie Shammas (লেখক), Tiffany Yang (লেখক), Alireza Abidi (লেখক), Malaika Amneus (লেখক), Melissa Hodeib (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2022-08-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Uterine leiomyosarcoma (uLMS) is an aggressive mesenchymal tumor associated with a poor prognosis. Research demonstrates that PARP inhibitors (PARPi) improve disease-stable survival in patients with somatic BRCA1/2 mutations through the process of synthetic lethality. Therefore, PARPi's may hav...